Main goal of the project
In reMIND, the University of Twente and the companies Demcon, Locsense, Micronit and Scinus Cell Expansion are working on four different but complementary technologies that contribute to the development of therapies for neurodegenerative diseases such as Alzheimer’s disease. The goal of reMIND is to develop and industrialize these technologies that contribute to the development of new treatment methods beyond the blood-brain barrier (BBB).
Further info
The blood-brain barrier forms the fysical boundary between the blood and the brain. This barrier is highly selective in allowing substances to pass through to the brain. Because of this BBB, it is very difficult to administer medication in the brain for the treatment of neurological disorders. The reMIND consortium has simulated a BBB on a chip to investigate whether it is possible to ‘open up’ the BBB with the help of ultrasonic triggering and microbubbles in order to be able to administer regenerative therapies or medication directly into the brain.
Website
No project website available.
Funding
This project has received funding from OP Oost, European Regional Development Fund.